Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Field of Science
- 3.1 Basic medicine
Fingerprint
Dive into the research topics where Viktorija Ulanova is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 3 Finished
-
Pharmacogenomics of drug resistant tuberculosis
Ranka, R. (Project leader), Bandere, D. (Leading expert) & Ulanova, V. (Leading expert)
1/04/22 → 30/04/23
Project: RSU grants
-
Tuberculosis treatment: exploring the perspectives for personalized therapy
Bandere, D. (Project leader), Ulanova, V. (Assistant (student)), Vīksna, A. (Assistant (student)) & Sadovska, D. (Assistant (student))
1/01/21 → 31/12/23
Project: Fundamental and Applied Research Programme
-
Assessment of genetic factors in tuberculosis cases
Ranka, R. (Project leader), Ulanova, V. (Participant), Aļeiņikova, D. (Participant) & Freimane, L. (Participant)
1/09/20 → 31/08/21
Project: RSU grants
-
Fluctuations in circulating cell-free mitochondrial and nuclear DNA copy numbers in blood plasma after anti-tuberculosis drug intake in patients with drug-susceptible tuberculosis
Freimane, L., Kivrāne, A., Ulanova, V., Vīksna, A., Sevostjanovs, E., Grīnberga, S., Cīrule, A., Krams, A. & Ranka, R. (Corresponding Author), Mar 2025, In: Tuberculosis. 151, 102611.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Downloads (Pure) -
Pharmacogenetic Aspects of Anti-Tuberculosis Therapy in Latvian Population
Ulanova , V., 2025, Rīga: Rīga Stradiņš University. 99 p.Research output: Student thesis › Doctoral Thesis
Open Access -
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships
Ulanova, V., Kivrane, A., Viksna, A., Pahirko, L., Freimane, L., Sadovska, D., Ozere, I., Cirule, A., Sevostjanovs, E., Grinberga, S., Bandere, D. & Ranka, R. (Corresponding Author), Mar 2024, In: Frontiers in Pharmacology. 15, 20 p., 1332752.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Citations (Scopus)19 Downloads (Pure) -
Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective
Kivrane, A. (Corresponding Author), Ulanova, V., Grinberga, S., Sevostjanovs, E., Viksna, A., Ozere, I., Bogdanova, I., Zolovs, M. & Ranka, R., 12 Mar 2024, In: Pharmaceutics. 16, 3, 388.Research output: Contribution to journal › Article › peer-review
Open AccessFile10 Downloads (Pure) -
Identification of Factors Determining Patterns of Serum C-Reactive Protein Level Reduction in Response to Treatment Initiation in Patients with Drug-Susceptible Pulmonary Tuberculosis
Kivrāne, A. (Corresponding Author), Ulanova, V., Grinberga, S., Sevostjanovs, E., Vīksna, A., Ozere, I., Bogdanova, I., Simanovica, I., Norvaisa, I., Pahirko, L., Bandere, D. & Ranka, R., Dec 2024, In: Antibiotics. 13, 12, 1216.Research output: Contribution to journal › Article › peer-review
Open AccessFile4 Downloads (Pure)
-
Assessment of Rifampicin Exposure in Latvian Pulmonary Tuberculosis Patients in the Context with AADAC Genetic Polymorphisms
Kivrāne, A. (Speaker), Ulanova, V. (Co-author), Grinberga, S. (Co-author), Sevostjanovs, E. (Co-author), Vīksna, A. (Co-author), Pole, I. (Co-author), Ozere, I. (Co-author), Bogdanova, I. (Co-author), Zolovs, M. (Co-author), Bandere, D. (Co-author) & Ranka, R. (Co-author)
29 Mar 2023Activity: Talk or presentation types › Poster presentation
-
Mapping the potential of pharmaco-metabolomics for personalized antituberculosis therapy
Igumnova, V. (Speaker)
24 Mar 2021Activity: Talk or presentation types › Oral presentation